The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 20, 2020

Filed:

Jul. 08, 2016
Applicants:

Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR;

Proteometech Inc., Seoul, KR;

Inventors:

Eun Wie Cho, Daejeon, KR;

Chang Kyu Heo, Daejeon, KR;

Hai Min Hwang, Daejeon, KR;

Jeong Heon Ko, Daejeon, KR;

Kook Jin Lim, Seoul, KR;

Hye Jung Lee, Seoul, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); C07K 16/18 (2006.01); A61P 35/00 (2006.01); C12N 5/16 (2006.01); C07K 16/30 (2006.01); G01N 33/58 (2006.01); G01N 33/564 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57438 (2013.01); A61P 35/00 (2018.01); C07K 14/4748 (2013.01); C07K 16/18 (2013.01); C07K 16/303 (2013.01); C12N 5/163 (2013.01); G01N 33/564 (2013.01); G01N 33/58 (2013.01); C07K 2317/14 (2013.01); C07K 2317/34 (2013.01); G01N 2800/52 (2013.01);
Abstract

Provided are an autoantibody specifically binding to an exosomal protein EIF3A (Eukaryotic translation initiation factor 3 subunit A) or a fragment including an antigen-binding site (paratope) thereof, a hybridoma cell line producing the autoantibody, a polypeptide having an amino acid sequence of an antigenic determinant (epitope) specifically binding to the autoantibody, a composition for diagnosing liver cancer including an agent measuring an expression level of the autoantibody or the fragment including the antigen-binding site thereof, a kit for diagnosing liver cancer including the composition, and a method of providing information for diagnosis of liver cancer by using the composition. Further, provided is a method of screening for a therapeutic agent for liver cancer by using an expression level of the autoantibody. When anti-EIF3A autoantibody of the present invention is used as a diagnostic marker for liver cancer, the incidence of liver cancer may be diagnosed at a high level only by using non-invasive biological samples. Furthermore, liver cancer may be easily diagnosed by using only the amino acid sequence identified in the present invention, leading to the effective development of diagnostic products such as a diagnostic kit for liver cancer.


Find Patent Forward Citations

Loading…